Chimeric antigen receptor (CAR) T-cell therapy—genetically engineered immune cells programmed to identify tumor antigens and induce a cytotoxic immune response—is being used in gradually more types of cancers. However, a new post-marketing study offers some caution: Cardiovascular and pulmonary adverse events (CPAEs) were commonly reported in addition to the well-known side effect of cytokine release syndrome.
The study, of 2,657 patients receiving CAR-T therapy whose side effects